Biomedical Research, Science, & Technology

The Early Childhood Workforce Data project highlights exemplary state activities that drive data use to address early childhood workforce issues, including the national early childhood workforce shortage. A U.S.

Team-based behavioral health care can effectively address clinical needs and mitigate behavioral health workforce shortages. Despite the demonstrated benefits of team-based care models, experts in the fields of behavioral health workforce and network adequacy have noted that existing reimbursement models do not adequately support team-based care.

RAND identified use cases on identifying frailty using electronic health record (EHR) data in health systems in the US and examples from other countries, which demonstrate applications in both primary and specialist care. The final EHR implementation guide summarizes the learnings from participants in the EHR Learning Network and the identified use cases.

The Office of the Assistant Secretary for Planning and Evaluation (ASPE) released a report summarizing lessons learned from surging the governmental public health workforce at state, tribal, local, and territorial (STLT) public health agencies during the COVID-19 pandemic.

The rise of artificial intelligence (AI) in health care and health care research has stimulated discussion on the application of trustworthy principles for AI. This report summarizes 15 considerations and 14 opportunities for the implementation of HHS’s trustworthy AI principles in patient-centered outcomes research projects that incorporate AI technology.

Development of novel antimicrobials has slowed, and the preclinical and clinical pipeline is likely to be insufficient to support current and future patient needs.

The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that are high expenditure, single source drugs without generic or biosimilar competition.

The market for antimicrobial (AM) drugs is unique in that it is associated with a positive externality (public health) as well as a negative externality (antimicrobial resistance, or AMR) (Mossialos, et al., 2010). AMR occurs when microbes change over time and no longer respond to available medicine.

It is well known that antimicrobial resistance (AMR) creates a substantial and ongoing public health and economic burden and understanding the size and nature of this burden is important for the ability to respond to the threat of AMR. However, estimating or projecting that burden within the U.S.

In 2017, at least 2.8 million people in the U.S. acquired serious infections with bacteria that are resistant to one or more antimicrobial drugs and 35,000 have died as a result. Resistance to antimicrobials is viewed as a global threat with antimicrobial drug use in human and animal health driving resistance.